X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ABBOTT INDIA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ABBOTT INDIA AUROBINDO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 18.9 40.2 47.0% View Chart
P/BV x 4.8 10.3 46.0% View Chart
Dividend Yield % 0.3 0.7 49.1%  

Financials

 AUROBINDO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
ABBOTT INDIA
Mar-18
AUROBINDO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs8956,110 14.6%   
Low Rs6223,996 15.6%   
Sales per share (Unadj.) Rs254.61,552.2 16.4%  
Earnings per share (Unadj.) Rs39.3188.8 20.8%  
Cash flow per share (Unadj.) Rs46.6196.4 23.7%  
Dividends per share (Unadj.) Rs2.5055.00 4.5%  
Dividend yield (eoy) %0.31.1 30.3%  
Book value per share (Unadj.) Rs160.0796.6 20.1%  
Shares outstanding (eoy) m585.8821.25 2,757.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.3 91.5%   
Avg P/E ratio x19.326.8 72.2%  
P/CF ratio (eoy) x16.325.7 63.3%  
Price / Book Value ratio x4.76.3 74.8%  
Dividend payout %6.429.1 21.8%   
Avg Mkt Cap Rs m444,390107,376 413.9%   
No. of employees `00014.03.3 420.9%   
Total wages/salary Rs m17,6783,937 449.0%   
Avg. sales/employee Rs Th10,667.89,929.3 107.4%   
Avg. wages/employee Rs Th1,264.31,185.1 106.7%   
Avg. net profit/employee Rs Th1,645.81,207.7 136.3%   
INCOME DATA
Net Sales Rs m149,15732,985 452.2%  
Other income Rs m1,1591,170 99.1%   
Total revenues Rs m150,31634,155 440.1%   
Gross profit Rs m34,3435,245 654.8%  
Depreciation Rs m4,276162 2,641.3%   
Interest Rs m66738 1,746.6%   
Profit before tax Rs m30,5586,215 491.7%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,5972,203 344.9%   
Profit after tax Rs m23,0124,012 573.6%  
Gross profit margin %23.015.9 144.8%  
Effective tax rate %24.935.4 70.1%   
Net profit margin %15.412.2 126.8%  
BALANCE SHEET DATA
Current assets Rs m92,06222,655 406.4%   
Current liabilities Rs m66,2236,681 991.2%   
Net working cap to sales %17.348.4 35.8%  
Current ratio x1.43.4 41.0%  
Inventory Days Days10665 163.6%  
Debtors Days Days6829 232.1%  
Net fixed assets Rs m62,919835 7,530.9%   
Share capital Rs m586213 275.7%   
"Free" reserves Rs m93,13316,715 557.2%   
Net worth Rs m93,71916,928 553.6%   
Long term debt Rs m1,8140-   
Total assets Rs m162,49424,162 672.5%  
Interest coverage x46.8163.7 28.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.4 67.2%   
Return on assets %14.616.8 86.9%  
Return on equity %24.623.7 103.6%  
Return on capital %32.736.9 88.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,838369 20,577.9%   
Fx outflow Rs m30,2243,807 794.0%   
Net fx Rs m45,613-3,438 -1,326.7%   
CASH FLOW
From Operations Rs m32,7861,527 2,147.1%  
From Investments Rs m-17,870-2,148 831.8%  
From Financial Activity Rs m-19,153-1,024 1,869.8%  
Net Cashflow Rs m-4,239-1,646 257.6%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.0 7.9 100.6%  
FIIs % 27.7 0.1 27,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.1 59.6%  
Shareholders   69,601 18,270 381.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS